Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
FUTURE EUROPEAN HEALTH-CARE - COST-CONTAINMENT, HEALTH-CARE REFORM AND SCIENTIFIC PROGRESS IN DRUG RESEARCH
Autore:
EMILIEN G;
Indirizzi:
WYETH AYERST RES,CNS DEPT PARIS FRANCE UNIV CATHOLIQUE LOUVAIN,CLIN UNIV ST LUC,DEPT NEUROL B-1200 BRUSSELS BELGIUM UNIV CATHOLIQUE LOUVAIN,CLIN UNIV ST LUC,PHARMACOL LAB B-1200 BRUSSELS BELGIUM
Titolo Testata:
The International journal of health planning and management
fascicolo: 2, volume: 12, anno: 1997,
pagine: 81 - 101
SICI:
0749-6753(1997)12:2<81:FEH-CH>2.0.ZU;2-Z
Fonte:
ISI
Lingua:
ENG
Soggetto:
PHARMACEUTICAL-INDUSTRY; UNITED-STATES;
Keywords:
PHARMACEUTICAL; ETHICS; HEALTH CARE REFORM; DEMOGRAPHICS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Physical, Chemical & Earth Sciences
Physical, Chemical & Earth Sciences
Citazioni:
37
Recensione:
Indirizzi per estratti:
Citazione:
G. Emilien, "FUTURE EUROPEAN HEALTH-CARE - COST-CONTAINMENT, HEALTH-CARE REFORM AND SCIENTIFIC PROGRESS IN DRUG RESEARCH", The International journal of health planning and management, 12(2), 1997, pp. 81-101

Abstract

The cost of the development of a new pharmaceutical product from its conception and synthesis through to the regulatory approval process has more than quadrupled in the last 20 years, Both clinical and total development times have increased substantially, To amortize the costs incurred, the pharmaceutical industry has taken an international dimension. The incentives for pharmaceutical firms to discover and develop new drugs depend on the length of the development and regulatory reviewprocess plus the potential market size. Recent regulatory, economic and political change may have significant implications for the future of new drug developments in Europe. The European Union industrial policy felt that there is a need for convergence in the area of pricing. Itis recommended that the policy should aim to contain growth in pharmaceutical expenses by means specific to reimbursement rather than to direct price controls. By encouraging doctors to prescribe and customersto use generics, competition is enhanced to bring down drug prices. More emphasis is being laid by government in educating customers to cost-awareness and cost-benefit ratios with regard to pharmaceuticals. Concerning clinical trials, European harmonization has been achieved by significant developments: the rights and integrity of the trial subjects are protected; the credibility of the data is established; and the ethical, scientific and technical quality of the trials has improved. Future European health care forecasts a whole change in the pharmaceutical business. Important issues in cost and outcome measurement shouldbe carefully planned and considered in drug development. Due to important mergers and acquisitions, the pharmaceutical sector will consist mainly of important multinational corporations. In this way, valuable new products may be brought to the market. ((C) 1997 by John Wiley & Sons, Ltd.).

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/12/20 alle ore 01:09:56